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Description of the evidence collection method
A review of the scientifi c literature was performed with the Me-
dline database. The search for evidence was based on actual cli-
nical scenarios and used the following Medical Subject Headings 
(MeSH) terms: Arthritis, Rheumatoid, Diagnosis (Delayed Diag-
nosis OR Delay OR Early Rheumatoid Arthritis OR VERA), Prog-
nosis, Criteria (American College of Rheumatology/European 
League Against Rheumatism OR ACR/EULAR OR classifi cation), 
Comparative Study, Smoking (OR tobacco use disorder), Rheu-
matoid Factor, Anti-cyclic Citrullinated Peptide (or anti-CCP), 
HLA-DRB1 OR PTPN22 OR EPITOPE, extra-articular OR extraar-
ticular OR systemic OR ExRA, Disease Progression, Radiography 
OR X RAY, ULTRASONOGRAPHY, and MAGNETIC RESONANCE
Grades of recommendation and strength of evidence
A: Most consistent experimental and observational studies.
B: Less consistent experimental and observational studies.
C: Case reports (uncontrolled studies).
D: Opinion that is not substantiated by critical evaluation, 
based on consensus, physiological studies or animal 
models.
Objective
To formulate guidelines for the management of rheumatoid 
arthritis (RA) in Brazil, with a focus on diagnosis. The aim of 
the present document is to summarise the current position of 
the Brazilian Society of Rheumatology on this topic to orient 
Brazilian doctors, particularly rheumatologists, to RA diagnosis 
in our country.
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive, and system-
ic infl ammatory disease that preferentially affects the synovial 
membranes of joints and eventually leads to bone and carti-
lage destruction1(D). RA affects 0.5%–1% of the adult popula-
tion worldwide; the disease targets patients from every ethnic 
background2(D) and predominately affects females (2- or 3-fold 
more often than males). Although RA can occur at any age, it 
is more frequent among individuals in the fourth to sixth de-
cades of life3(D).
A Brazilian multicentre study conducted with samples 
from the various macro-regions found a prevalence of up 
to 1% in Brazil’s adult population4(B), which corresponds to 
1,300,000 people.
As a chronic disease that causes irreversible joint damage, 
RA exacts high costs from both the patients and society at 
large 5(B) 6,7(D).
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In recent years, signifi cant advances have been achieved 
in understanding the physiopathogenesis, diagnostic meth-
ods, and therapeutic management of RA. Among these ad-
vances, the recently attributed signifi cance of the early disease 
stages or so-called early RA (fi rst 12 months with RA symp-
toms) stands out as an acknowledged “window of therapeutic 
opportunity”8(B)9,10(D). However, despite all advances, the cur-
rently available (clinical, laboratory, and radiological) diagnos-
tic and prognostic indicators are of limited value to early diag-
noses and individual prognoses11(B).
The demographic and clinical features of RA vary as a func-
tion of the affected population12(B). Most available data corre-
spond to populations in Europe and the United States13,14(D). Few 
studies have been conducted on the Brazilian population15,16(B).
RA affects mostly individuals within the economically pro-
ductive age range, and the disease eventually imposes signifi -
cant limitations on their functional ability that result in the 
loss of work abilities. For these reasons, the indirect costs as-
sociated with RA must be included in pharmacoeconomic 
studies17(B).
In Brazil and industrialised countries, the costs associated 
with RA are high18(B). The impact of the expenses associated 
with RA is more remarkable in developing countries in which 
the fi nancial resources allocated to healthcare are less robust. 
This situation points to the relevance of studies adapted to 
Brazilian conditions that assess the costs and allocation of re-
sources for the diagnosis and treatment of RA19(B).
RA diagnosis is based on clinical fi ndings and complemen-
tary diagnostic tests. No single laboratory, imaging, or histo-
pathological test alone can confi rm a diagnosis.
Several illnesses that present with arthritis must be con-
sidered in the differential diagnosis of RA20-22(D), as described 
in Table 1.
Diagnosis is easier when RA presents with the well-known 
pattern and the full range of typical symptoms. Diagnosis 
might be diffi cult in the early stages of disease because the 
characteristic serologic and radiological alterations are often 
absent23(D).
The clinical manifestations of RA can be classifi ed as ar-
ticular and extra-articular. As RA is a systemic disease, general 
symptoms such as fever, asthenia, fatigue, myalgia, and weight 
loss can appear before or concomitantly with the onset of the 
articular manifestations24(D).
Articular manifestations 
Although the articular manifestations of RA might be revers-
ible in the early stages, persistent and uncontrolled synovitis 
leads to bone and cartilage destruction and irreversible tendon 
and ligament injuries. 
The basic factor behind RA articular manifestations is syno-
vial infl ammation (synovitis), which can affect any diarthrodial 
joint in the body. 
The clinical complaints include pain, swelling, and motion 
limitations of the affected joints. A physical examination will 
disclose the presence of pain, increased joint volume, intra-
articular effusion, heat, and eventual redness. Those fi nd-
ings might not be evident in deep joints such as the hips and 
shoulders24(D).
The characteristic features of arthritis in RA are as 
follows24(D):
a) Polyarticular affection: usually involving more than four 
joints. Nevertheless, RA might begin and eventually re-
main as mono- or oligoarthritis.  
b) Hand and wrist arthritis: affections of the wrist, metacar-
pophalangeal (MCP), and proximal interphalangeal (PIP) 
joints are frequent from the very early disease stages. The 
distal interphalangeal (DIP) joints are seldom affected, a 
feature that distinguishes RA from other conditions such 
as osteoarthritis and psoriatic arthritis. 
c) Symmetric arthritis: symmetric affection of joints is a 
common fi nding, although not mandatorily absolute in 
cases of the PIP, MCP, and metatarsophalangeal (MTP) 
joints.
d) Cumulative or additive arthritis: arthritis usually exhibits 
a cumulative pattern (progressive affection of new joints 
concomitant to infl ammation of the previously affected 
ones). 
e) Morning stiffness: prolonged stiffness that appears in the 
morning, which is accompanied by a sensation of swelling, 
is near-universal feature of synovial infl ammation. Unlike 
the short-lasting (5–10 minutes, as a rule) variety observed 
in osteoarthritis, in infl ammatory diseases, stiffness tends 
to last for more than 1 hour. This phenomenon is asso-
ciated with immobility that occurs concomitantly to the 
state of sleep or rest, rather than to a particular time of the 
day. The duration of stiffness tends to correlate with the 
degree of infl ammation and is an important parameter in 
follow-up evaluations25(B)26(C).
Extra-articular manifestations
Although the articular manifestations are the most charac-
teristic, other organs and systems can also be affected by 
RA. The most common extra-articular manifestations of 
Table 1 – Differential diagnoses of arthritis.
Classes of diseases Diseases 
Infections Viral (e.g. dengue, human 
immunodefi ciency virus – HIV, 
parvovirus, cytomegalovirus, hepatitis), 
bacterial (e.g. N. gonorrhoeae, S. aureus), 
microbacterial, fungal, and others 
Spondyloarthritis Reactive arthritis (Chlamydia, Salmonella, 
Shigella, Yersinia), ankylosing spondylitis, 
psoriatic arthritis, enteropathic arthritis 
Systemic rheumatic 
diseases
Systemic lupus erythematosus, 
polymyositis/dermatomyositis, systemic 
sclerosis, Sjögren’s syndrome, Behçet’s 
disease, rheumatic polymyalgia, systemic 
vasculitis, and others 
Microcrystalline 
arthritis
Gout, calcium pyrophosphate deposition 
disease, and others 
Endocrine diseases Hypothyroidism, hyperthyroidism 
Neoplastic diseases Metastatic neoplastic disease, lymphoma, 
paraneoplastic syndromes, and others
Others Osteoarthritis, haemochromatosis, 
amyloidosis, sarcoidosis, serum sickness
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RA include skin, eye, pleuropulmonary, heart, blood, neuro-
logical, and osteo-metabolic conditions. These occur more 
often in patients with severe and polyarticular disease, 
positive serology for the rheumatoid factor (RF) or cyclic 
citrullinated peptide antibodies (anti-CCP), and rheumatoid 
nodules27(B)28(D).
Brazilian studies confi rmed that the initial manifestations 
of RA include polyarticular affection with persistent synovitis 
in the hands, long-lasting morning stiffness, a large number 
of painful and swollen joints, and fatigue15,16(B).
1. Is diagnosis of RA within the fi rst 12 months 
of symptoms (early RA) associated with better 
radiological and functional prognosis, compared 
to later diagnosis?
The modern differentiation of RA from other joint diseases 
dates from 1907. As no pathognomonic traits allow a distinc-
tion among the various types of arthritis in their early stages, 
the exact moment at which RA begins to progress as a sepa-
rate entity from other articular illnesses is unknown12(B).
The defi nition of early RA is important from both the the-
oretical and practical perspectives, although the terms “ear-
ly” and “RA” might be addressed independently, particularly 
because the criteria applied to these classifi cations are based 
on established RA13(D).
Although controversial, early RA might be defi ned as the 
initial stage of disease or a “window of therapeutic opportu-
nity” in which adequate therapy might modify the disease 
progression; the prognosis in this stage is better than that of 
later stages14(D).
The required symptom duration for the defi nition of early 
RA varies widely in the specialised literature. Historically, any 
RA of a duration less than fi ve years has been characterised 
as “early”15(B). However, together with the notion of a “win-
dow of opportunity”, the original length of early RA needed 
to be restricted. Starting in the early 90’s, early RA was con-
sistently defi ned as the presence of symptoms for less than 
24 months, with the main emphasis on the fi rst 12 months of 
clinical manifestations16(B).
The current indications are to assess patients with ar-
ticular symptoms as soon as possible and to limit the early 
stage of RA to the fi rst weeks or months of symptoms (as a 
rule, less than 12 months). In particular, the fi rst 12 weeks 
are a critical period known as “very early” RA (VERA), while 
patients with more than 12 weeks but fewer than 12 months 
of articular symptoms are classifi ed as so-called “late early 
RA” (LERA)17(B).
The proportion of rheumatologists with opportunities to 
assess patients within the fi rst six weeks of symptoms in-
creased from 9% in 1997 to 17% in 2003; however, not every 
case is liable to such early assessment18(B).
Even while admitting imprecisions in the defi nition of 
early RA, several authors have suggested that a substantial 
proportion of the cases with short-lasting (less than eight 
weeks) infl ammatory arthritis exhibit spontaneous reso-
lution, while only the few patients with persistent clinical 
manifestations progress into proper RA19(B)20-22(D). Thus, the 
establishment of clinical, serologic, or genetic markers that 
can identify patients who will progress to RA at the earliest 
stages and consequently will need appropriate treatments to 
reduce the odds of developing persistent disease and articu-
lar damage is of paramount importance. 
The average time for the fi rst visit of RA patients with a 
rheumatologist is 17 months, and 19 months usually elapse 
before the fi rst administration of disease-modifying anti-
rheumatic drugs (DMARDs). Factors such as education, the 
number of swollen joints, age, and occupation are associated 
with such delays29(B).
Arthritis is characterised by articular swelling that is as-
sociated with pain or stiffness. Cases that involve more 
than one articulation should be referred to a rheumatolo-
gist, ideally within the fi rst six weeks following the onset of 
symptoms30(D).
For cases in which articular swelling was present only dur-
ing the fi rst year of disease, the risk of articular erosion was 
reduced by fi ve years (NNT: 4), compared to those patients 
with joint swelling throughout the follow-up period31(B).
RA diagnosis within the fi rst three months of VERA was 
predictive of clinical (American College of Rheumatology – 
ACR) and radiological (Sharp score) remission32(B).
The early identifi cation of some factors allows clinicians 
to predict whether the RA lesions will exhibit radiological 
progression in the following 12 months. These factors in-
clude the Sharp score and modifi ed Total Sharp Score (mTSS), 
the presence of autoantibodies such as RF and anti-CCP, and 
increased acute-phase reactants such as an erythrocyte sedi-
mentation rate (ESR) greater than 28 mm and an average C-
reactive protein (CRP) level of 10 mg/L33(B).
The higher the erosion score at the onset of treatment, the 
worse the 10-year radiological prognosis (Sharp score)34(B).
Early (within the fi rst year) calculations of the Sharp, ero-
sion, and reduced joint space scores permitted predictions 
of the radiological progression of RA patients who were fol-
lowed-up for three years35(B).
In spite of the early (three to six months from the begin-
ning of symptoms) administration of DMARD treatment, 
63.6% of the patients exhibited erosion three years later due 
to constitutional factors such as the presence of autoanti-
bodies  (e.g. RF or anti-CCP) and the length of disease activity 
(CRP, joint swelling, and response to treatment)36(B).
The duration of RA interferes with the functional progno-
sis, which is measured by means of the Health Assessment 
Questionnaire (HAQ) and is independent of the baseline 
values37(B).
When DMARD treatment was initiated within the fi rst 
year of disease (average symptom duration, six months), the 
radiological progression (Ratingen score) was reduced at the 
5-year follow-up38(B).
In patients with symptom durations less than 12 weeks 
who were treated for RA, the radiological progression (Sharp-
van der Heijde score, SHS) was reduced after six years of fol-
low-up. Sustained DMARD-induced remission was 8% higher 
(NNT: 13) in patients with symptom durations less than 12 
weeks39(B).
DMARD treatment of RA patients within the fi rst year 
of disease induced better functional (Keitel Functional Test 
– KFT) and clinical (joint swelling) progression at a 10-year 
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follow-up, compared to those who were treated one to fi ve 
years after disease onset40(B).
Recommendation
Diagnosis of RA with a symptom duration of less than 12 
months (early RA) is of paramount importance because early 
diagnosis exerts benefi cial effects on radiological and func-
tional prognoses compared to later diagnosis. 
2. Are the new 2010 ACR/European league against 
rheumatism (EULAR) classifi cation criteria for RA 
superior to the 1987 classifi cation criteria for the 
early disease stage?
RA classifi cations were essentially based on the criteria for-
mulated by the ACR in 198741(B), which are described in Table 
2. However, those criteria did not perform well in early RA 
cases42(B). The ACR classifi cation criteria for RA were based on 
individuals with long-standing disease and, until then, were 
considered to be the standard for the selection of patients 
for clinical studies. These criteria exhibit 91%–94% sensitivity 
and 89% specifi city for established RA. However, some of the 
items, such as radiological changes (erosions) and rheumatoid 
nodules, do not occur often in early RA. Thus, such criteria are 
suboptimal for the identifi cation of individuals with early RA 
(40%–90% sensitivity, and 50%–90% specifi city)43(B).
As a result, new RA classifi cation criteria were needed, with 
a special focus on the early disease stages14(D).
The new ACR/EULAR classifi cation criteria can be applied 
to any patient, provided that two basic requirements are met 
as follows:
1) Evidence of active clinical synovitis in at least one joint at 
the time of examination.
2) Synovitis cannot be better explained by another disease.
The new criteria (Table 3) are based on a score system that 
is calculated by direct addition. The clinical manifestations are 
grouped into the following four domains: joint involvement, 
serology, duration of symptoms, and acute-phase reactants. In 
questionable cases, the number of involved joints can be cal-
culated by the use of imaging methods such as ultrasound (US) 
and magnetic resonance (MRI). A score > 6 is needed to classify 
a patient as having defi nite RA44(B). These criteria can be ap-
plied both prospectively and retrospectively, provided that the 
data were properly recorded.  
It is worth observing that whenever a patient exhibits typi-
cal erosions upon radiological examination and a clinical his-
tory compatible with RA (albeit non-documented), RA diagno-
sis can be directly established in a manner independent of the 
applicability of the classifi cation criteria14(D).
The new 2010 criteria were not developed for the purpose 
of diagnosis but rather of classifi cation. The criteria basically 
serve to select homogeneous populations for studies.  
Clinical RA diagnoses are extremely complex and includes 
multiple features that are hard to reconcile with a single scor-
ing system14(D). Eventually, the formal criteria might serve to 
guide clinical diagnoses. 
Several features of the new criteria must be subjected to 
careful analysis before they can be universally accepted. In par-
ticular, the criteria must be validated in different populations, 
including Brazilian early RA cohorts. 
In patients who use methotrexate and those with persistent 
RA, the discriminatory powers of the 2010 ACR/EULAR criteria 
were 76% and 87%, respectively, when the score was at least 6, 
and 63% and 46%, respectively, when it was < 645(B).
Assuming the need for methotrexate, a diagnostic gold 
standard, during the fi rst year of follow-up, the 2010 ACR/EU-
LAR criteria were able to diagnose 86% of the cases for which 
the score was at least 6 and 49% when it was < 645, compared 
to 87% and 41%, respectively, when the 1987 ACR criteria were 
used46(B).
A comparison of the 2010 ACR/EULAR (score of at least 6) 
and 1987 ACR (score > 4) criteria relative to the diagnosis of pa-
tients with a disease duration of less than 12 months showed 
positive predictive values of 70.7% and 65.3%, respectively, and 
negative predictive values of 76.1% and 79.1%, respectively47(B).
The discriminatory powers of the 2010 ACR/EULAR and 1987 
ACR criteria during an 18-month follow-up period were com-
pared and are shown in Table 4. 
The application of the 2010 ACR/EULAR criteria at disease 
onset detected more patients who required DMARD treatment 
than did the 1987 ACR criteria; the values were  62% and 38%, 
respectively, and more particularly with regard to the use of 
methotrexate during the 18-month follow-up, the values were 
68% versus 42%, respectively. However, the 2010 ACR/EULAR 
criteria were associated with a higher rate of false-positive 
cases (8% versus 2% for the 1987 ACR criteria)48(B).
Table 2 – 1987 American College of Rheumatology 
classifi cation criteria for rheumatoid arthritis.
Criteria Defi nition
1. Morning stiffness Morning stiffness lasting at least 1 hour 
before maximal improvement
2. Arthritis of 3 or more 
joint areas
At least three joint areas simultaneously 
affected and observed by a physician. 
The possible areas include the right or 
left PIP, MCP, wrist, elbow, knee, ankle, 
and MTP joints. 
3. Arthritis of hand joints Arthritis in wrist, MCP, or PIP joint
4. Symmetric arthritis Simultaneous involvement of the same 
joint areas on both sides of the body. 
5. Rheumatoid nodules Subcutaneous nodules over bony 
prominences, extensor surfaces, or in 
juxta-articular regions as observed by 
a physician
6. Serum rheumatoid 
factor
Demonstration of abnormal amounts of 
serum rheumatoid factor. 
7. Radiographic changes Radiographic changes typical 
of rheumatoid arthritis on 
posteroanterior hand and wrist 
radiographs showing juxta-articular 
bone thinning or erosions
For classifi cation purposes, a patient shall be said to have rheumatoid 
arthritis if he/she has satisfi ed at least four or these seven criteria. 
Criteria 1 through 4 must have been present for at least six weeks. 
Modifi ed from: Arnett FC, Edworthy SM, Bloch DA, McShane DJ, 
Fries JF, Cooper NS et al. The American Rheumatism Association 
1987 revised criteria for the classifi cation of rheumatoid arthritis. 
Arthritis Rheum. 1988;31:315-24.
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In cases for which the 1987 ACR criteria had been used to 
defi ne RA (without radiological aid), the 2010 ACR/EULAR cri-
teria were diagnostic of disease in 59% of the cases (positive 
predictive value), and ruled out the diagnosis in 93% (negative 
predictive value). The rate of false-positive results for the 2010 
ACR/EULAR criteria was 17%. If RA was considered a chronic 
disease (fi ve years of follow-up), the discriminatory power of 
the 2010 ACR/EULAR criteria fell to 68% when the score was at 
least 6 and to 61% when the score was < 6. Nevertheless, the 
1987 ACR criteria identifi ed 11.3% fewer cases as RA than did 
the 2010 ACR/EULAR criteria49(B).
Recommendation 
The 2010 CR/EULAR criteria identify more patients with 
early RA than do the 1987 ACR criteria. However, the rate of 
false-positive cases is higher with the newer criteria. When 
follow-up criteria such as use of DMARDs or disease persis-
tence are used, the discriminatory powers of the 2010 CR/
EULAR and the 1987 ACR criteria are similar. 
3. Is smoking associated with a poorer prognosis 
for articular disease in RA patients?
Smoking was found to increase the risk of non-response 
(ACR50) by 18.3% [number needed to harm (NNH): 6] in pa-
tients with early RA (24 weeks of symptom duration)50(B).
According to the EULAR criteria, RA patients who were 
smokers were less likely to achieve a good response at three 
months of treatment, compared to the non-smokers (NNH: 11). 
The patients who continued to smoke exhibited lower odds 
Table 3 – 2010 ACR/EULAR classifi cation criteria for rheumatoid arthritis.
Target population (Who should be tested?) Patients who meet the following criteria:
1) Have at least 1 joint with defi nite clinical synovitis (swelling)*
2) Present with synovitis that is not better explained by another disease
*Differential diagnoses might include conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If the relevant 
differential diagnoses to consider are unclear, an expert rheumatologist should be consulted.
Joint involvement (0–5) Serology (0–3) Duration of symptoms (0–1) Acute-phase reactants (0–1)
1 large joint 0 Negative RF AND negative 
ACPA
0 < 6 weeks 0 Normal CRP AND normal 
ERS
0
2–10 large joints 1 Low-positive RF OR low-
positive ACPA 
2 ≥ 6 weeks 1 Abnormal CRP OR 
abnormal ERS
1
1–3 small joints (large 
joints are not taking 
into account)
2 High-positive RF OR high-
positive ACPA
3
4–10 small joints (large 
joints are not taking 
into account )
3
> 10 joints (at least 1 
small joint)
5
A score ≥ 6 is needed for the classifi cation of a patient with defi nite RA. “Joint involvement” refers to any swollen or tender joint on 
examination, which might be confi rmed by imaging evidence of synovitis. Distal interphalangeal joints, fi rst carpometacarpal joints, and fi rst 
metatarsophalangeal joints are excluded from assessment. “Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal 
joints, second through fi fth metatarsophalangeal joints, thumb interphalangeal joints, and wrists. “Large joints” refers to the shoulders, 
elbows, knees, and ankles. In the category “> 10 joints” at least one of the involved joints must be a small joint; the other joints can include 
any combination of large and additional small joints, as well as joints that are not specifi cally listed elsewhere (e.g., temporomandibular, 
acromioclavicular, sternoclavicular). 
In “Serology”, negative refers to IU values of the rheumatoid factor or anti-citrullinated protein antibody that are less than equal to the upper 
limit of normal (ULN) for the laboratory and assay, low-positive refers to IU values that are higher than the ULN, but ≤ 3 times the ULN for the 
laboratory and assay, and high-positive refers to IU values that are ≥ 3 times the ULN for the laboratory and assay. 
“Duration of symptoms” refers to patient self-reports of the duration of signs or symptoms of joint synovitis that are clinically involved at the 
time of assessment.
“Acute-phase reactants” (erythrocyte sedimentation rate, and C-reactive protein) are considered to be normal/abnormal according to the local 
laboratory standards. 
Modifi ed from: Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd. 2010 rheumatoid arthritis classifi cation criteria: an 
American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9):1580-8.
Table 4 – Positive and negative predictive values from the 1987 ACR and 2010 ACR/EULAR criteria for patients with 
rheumatoid arthritis who are using disease-modifying anti-rheumatic drugs at the onset of disease and 18 months later.
Measurement Cohort onset 18 months later
2010 ACR/EULAR 1987 ACR 2010 ACR/EULAR 1987 ACR
+ predictive value 75% 85% 73% 81%
- predictive value 66% 59% 69% 79%
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of good treatment responses during a 5-year follow up period. 
That difference in good treatment responses was somewhat 
higher in patients who were treated with anti-tumour necrosis 
factor (TNF) (14%; NNH: 7)51(B).
Smokers tend to exhibit more extra-articular manifesta-
tions of RA (pleuritic, pericarditis, interstitial lung disease, 
neuropathy, glomerulonephritis, vasculitis), compared to non-
smokers, as well as higher average Disease Activity Score (DAS-
28), and Health Assessment Questionnaire (HAQ) values 52(B).
Smoking increased the use of DMARDs in RA patients and 
reduced their clinical responses (ACR50) by 16% (NNH: 6), par-
ticularly in smokers of more than 20 packages/year53(B).
The radiological progression of RA was similar in smokers 
and non-smokers after three years, which did not agree with 
the poorer clinical responses exhibited by the former54(B).
RA patients who were smokers exhibited greater disease ac-
tivity (joint pain and swelling) when compared to non-smokers 
after 24 months of treatment. The pain scores [(on a visual ana-
logue scale – VAS) were also higher among the smokers. How-
ever, radiological progression did not differ between smokers 
and non-smokers55(B).
Disease activity (measured as joint swelling, pain, and DAS-
28) was greater in patients with an average symptom duration 
of seven months who were smokers when compared to non-
smokers after a 5-year follow-up56(B). 
Recommendation
Smoking increases the disease activity of RA and reduces clini-
cal and functional responses over time. However, there is no 
suffi cient evidence regarding its infl uence on radiological dis-
ease progression. 
4. Is measurement of the rheumatoid factor 
a reliable test for diagnosis and prognostic 
stratifi cation in RA?
RF is an antibody that targets the Fc fragment of IgG57(D). RF 
is classically associated with RA, is found in the serum of ap-
proximately 70% of RA patients, and is signifi cantly correlated 
with a poorer prognosis. High RF levels are associated with 
aggressive disease, the presence of rheumatoid nodules, and 
extra-articular manifestations58(D).
The diagnostic value of RF alone is limited because 30%–
50% of patients might be seronegative during the early stage of 
RA57(D). In addition to its low sensitivity, its specifi city is lim-
ited. Individuals without RA might test positive for RF, and its 
prevalence increases with age59(B). Patients with other medical 
conditions, both rheumatologic and not, might also test posi-
tive for RF44,60(B). Therefore, negative RF serology does not rule 
out a diagnosis of RA, whereas the interpretation of positive 
results must be carefully checked against the clinical fi ndings. 
Brazilian data (incident early RA cohort) indicate a RF preva-
lence of approximately 50% in patients 61(B).
RF-positive patients with RA exhibited a 17% increase of 
mortality (NNH: 6) and cardiovascular mortality (NNH: 6) after 
20 years of follow-up62(A).
The mortality of RA patients with RF-positive serology did 
not differ from that of seronegative patients after 14 years of 
follow-up. However, when the results were analysed according 
to the number of expected events in the population, the mor-
tality, and more specifi cally the cardiovascular mortality, was 
elevated in the RF-positive patients 63(B).
A 10-year follow-up study of RA patients, in which 24% of 
the cases tested positive for RF of the IgM and IgA isotypes, 
found that radiological progression was associated with and 
could be predicted by the serological fi ndings (e.g. IgM or 
IgA)64(B).
In a population of RA patients, 51% of whom were RF-posi-
tive, the presence of RF was predictive of radiological progres-
sion in 69% of the cases, whereas its absence ruled out progres-
sion in 83%. 
RF was predictive of radiological progression (Larsen score) 
in RA patients after 5 years of follow-up65(B).
RF was predictive of radiological progression (Sharp or Lars-
en scores)35,66(B) and the need for biological therapy67(B) in RA 
patients after three years of follow-up.
The risk of radiological progression was 24.3% (NNH: 4) high-
er among RF-positive patients versus RF-negative patients68(A).
With a pre-test RA probability rate of 35%, positive RF (IgM, 
IgA, and IgG isotypes), measured by ELISA, increased the diag-
nostic probability rate to 94%, while negative serology ruled out 
RA with an 85% certainty rate69(B).
In a population of patients with a 35% probability rate of 
RA, RF (IgM, IgA, and IgG isotypes) increased the post-test prob-
ability to 96%70(B).
Recommendation
RF measurement contributes estimations of prognosis for RA 
patients, particularly with regard to radiological progression 
and mortality. Positive RF serology, particularly in populations 
with a pre-test probability rate of 35%, increased the diag-
nostic probability to 94%–96%, whereas negative RF serology 
ruled RA out with a post-test probability of 85%. 
5. Is anti-CCP investigation superior to 
rheumatoid factor investigation for RA diagnosis?
Recently, several anti-citrullinated protein antibodies (ACPA) 
were shown to behave as important diagnostic tools for 
RA; these had a similar sensitivity and superior specifi city 
to RF, in addition to their possible participation in disease 
physiopathogenesis71(B). Their possible roles as markers of RA 
activity are controversial72(B).
Cyclic citrullinated peptide antibodies 
Among the investigated antibodies that target fi laggrin-ci-
trulline system antigens, anti-CCP exhibits the widest clini-
cal applicability, with 70%–75% sensitivity and approximate-
ly 95% specifi city. Anti-CCP analyses are particularly useful 
for patients with early RA and negative RF serology73(B).
Anti-CCP measurements are also valid in investigations 
of undifferentiated arthritis. These antibodies are detect-
ed very early in the course of RA, and thus might be used 
as markers for progression and disease prognosis41-43,74-
78(B)21,79(D).
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Other antibodies
Other antibodies are also used to investigate RA. The aim is 
to develop methods with sensitivities and specifi cities sat-
isfactory for early disease diagnosis, as well as more reli-
able markers for activity and prognosis. These antibodies 
include anti-mutated citrullinated vimentin (anti-MCV)80-
82(B), anti-keratin (AKA), anti-perinuclear factor (APF)83(B), 
anti-fi laggrin84(B), anti-citrullinated fi brinogen (ACF)85(B), anti-
protein A2 of the heterogeneous nuclear ribonucleoprotein 
complex (anti-RA33)83(B), anti-interleukin 1 (anti-IL1)86(B), 
anti-1-α-enolase87(B), and anti-advanced glycation end-prod-
uct (AGE)88(B). The specifi cities of these antibodies are gen-
erally satisfactory for RA diagnosis, but their sensitivities is 
generally lower than that of anti-CCP.
The 2010 ACR/EULAR criteria14(D) include only RF and ACPA 
under the heading “autoantibodies”, and the values of these 
antibodies are described as negative, low, or high titres. As 
the values of both RF and anti-CCP are expressed as interna-
tional units (IU), the results are rated negative when they are 
equal to or higher than the upper limit of normal (ULN) in the 
corresponding laboratory; low-positive when they are higher 
than the ULN, but equal to or lower than 3 times the ULN; and 
high-positive when they are higher than three times the ULN. 
Positive anti-CCP correlated with the MRI swelling and ero-
sion score at a 4-year follow-up, whereas negative anti-CCP 
correlated with the synovitis score89(B).
Anti-CCP was superior to RF for predictions of the progres-
sion of undifferentiated arthritis into RA (diagnostic certain-
ties of 93% and 68%, respectively). The former also permitted 
better estimates of the severity of disease at a 7-year follow-
up90(B).
The risk of positive anti-CCP serology in patients with ac-
tive RA is 23% higher than that of patients in the period before 
disease. The anti-CCP alterations did not change after seven 
years of follow-up91(B).
With regard to the use of anti-CCP (second generation, 
anti-CCP2) and data from 15 recent RA cohorts, it was con-
cluded that a single positive result permits a diagnosis of RA 
(likelihood ratio, LR+ 12.7), but that a single negative result 
does not rule out RA (LR− 0.45). Upon comparing RF and anti-
CCP2, we found that their sensitivities are similar (56% and 
58%, respectively), but the specifi city of anti-CCP2 is superior 
(96% versus 86% for RF). The sensitivity and specifi city of anti-
CCP2 are higher than those of anti-CCP1. The combination of 
positive RF and anti-CCP2 only slightly increases the diagnos-
tic certainty, compared to anti-CCP2 alone (LR+ 27 versus 22, 
respectively). An analysis of global evidence allows us to esti-
mate the sensitivity of anti-CPP2 a 67%, and the specifi city as 
96%. Assuming a prevalence of 42% in RA patients according 
to the 1987 ACR criteria, positive anti-CCP2 serology increases 
the diagnostic certainty to 90%, and negative serology rules 
out RA with a certainty of 75%92(B).
Recommendation
The sensitivity of anti-CCP is similar to that of RF, but the speci-
fi city of the former is superior, especially in the early disease 
stages. Anti-CCP evaluations are recommended in patients 
with a clinical suspicion of RA and negative RF test serology. 
6. Are genetic markers (evaluations of HLA-DRB1 
shared epitope alleles and PTPN22 genes) useful 
for characterisations of RA patients with poorer 
prognosis?
Although countless genetic markers have been described in as-
sociation with RA, only the HLA-DRB1 shared epitope (SE) 10The 
presence of SE (HLA-DRB1) in RA patients did not correlate with 
radiological disease progression105,107(B). However, according to 
some data, SE alleles and anti-CCP antibody levels might be as-
sociated with the severity of joint damage (erosion and radio-
logical damage score) in RA patients108(B). The HLA SE had no 
predictive value relative to radiological RA progression109(B).
The frequency of HLA-DRB1 alleles with SE was found to be 
high in Latin American RA patients110(B).
The presence of SE alleles (DRB1) might be predictive of mor-
tality, including cardiovascular mortality, in RA patients with 
RA111,112(B).
An association was found between the DRB1 genotype 
and RF-positive RA patients with a 3.0%–3.7% (NNH: 30) risk 
increase113(B).
Recommendation
The PTPN22 gene polymorphism is associated with RA. Al-
though it is not predictive of specifi c therapeutic responses 
to biological therapy, it is predictive of remission when as-
sociated with anti-CCP. Alone or in combination with HLA-
DRB1 (SE), the PTPN22 polymorphism permits estimations of 
radiological progression or disease activity. The HLA-DRB1 al-
lele seems to play a more important role in the prediction of 
poor prognosis relative to the progression, activity, severity, 
and mortality of RA. 
7. Does the occurrence of extra-articular 
manifestations denote a more aggressive disease 
progression?
Although articular manifestations are the most characteristic, 
RA can also affect other organs and systems. The most fre-
quent extra-articular manifestations include skin, eye, pleu-
ropulmonary, heart, blood, neurological, and osteo-metabolic 
conditions. These occur more often in patients with severe 
and polyarticular disease, positive RF or anti-CCP serology, and 
rheumatoid nodules27(B)28(D).
The incidence of extra-articular manifestations in RA is 
47.5%, which includes cardiovascular, blood, eye, and lung af-
fections. Such manifestations are associated with a greater 
likelihood of the use of biological agents114(B).
Clinically signifi cant lung interstitial disease occurs in 10% 
of RA patients115(B). Patient mortality depends on the type of 
lung affection and is greater when the affection is diffuse116(B). 
Pulmonary fi brosis-related mortality is approximately 6%115(B). 
The average survival of patients with interstitial pneumonia is 
3.2 years, and thus is generally lower compared to that of other 
varieties of interstitial disease (6.6 years)116(B). In RA patients 
with lung interstitial disease, anti-TNF drugs must be used 
cautiously due to the risk of increased mortality117(B).
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The mortality rate of RA patients with lung interstitial dis-
ease is 7%, and the average survival duration after diagnosis 
is three years. In spite of the association between interstitial 
lung disease and RA activity, the latter was only denoted by 
increased ESR in that study118(B).
The presence of kidney dysfunction in RA patients is not as-
sociated with the activity, progression, dysfunction, or severity 
of the disease119(B).
RA patients with extra-articular manifestations exhibit a 
20% increase in the risk of cardiovascular events (including 
acute myocardial infarction, angina, coronary disease, and 
stroke) (NNH: 5)120(B).
The survival of patients with extra-articular manifestations 
of RA (18% of cases) is lower than that of patients with exclu-
sive articular manifestations, and the relative risk of death in 
the former increases by 27% after seven years of follow-up. 
Similar to the extra-articular manifestations, comorbidities 
also increase mortality, particularly cardiovascular conditions 
because these cause 31% of patient deaths. Increased mortal-
ity correlates with greater disease activity (RF), worse function 
(HAQ), and increased radiological progression121(B).
In RA patients with extra-articular manifestations, the 
scores that assess disease activity, such as DAS28 and HAQ, 
and the Larsen radiological score tend to be poorer, thus de-
noting a greater disease severity. Only 4.1% of such patients 
achieved remission122(B).
After 15 years of follow-up, mortality increased only in the 
patients with extra-articular manifestations (relative risk in-
crease: 51%), compared to those without such conditions; peri-
carditis was the most signifi cant of the manifestations123(B).
The mortality rate of RA patients with extra-articular mani-
festations (7.9% prevalence) was one death per 4.3 patients per 
year, whereas the rate of patients without articular manifesta-
tions was one death per 11.4 patients per year124(B).
The risk of severe gastrointestinal diseases is elevated in RA 
patients with extra-articular manifestations (4.6% prevalence). 
In such patients, the disease intensity (ACR criteria) and the 
signs of radiological progression are also greater125(B).
Recommendation
RA progression is more severe in patients with extra-articular 
manifestations. These patients have more intense disease ac-
tivity with reduced functional capacities, responses to treat-
ment (less occurrence of remission), and life expectancies, 
compared to those with exclusive articular manifestations. 
8. Is conventional radiography an appropriate test 
for RA diagnosis?
Conventional radiography is the most widely used imaging 
method for assessments of structural joint damage in RA. In 
addition to its diagnostic utility, conventional radiography 
plays an important role in the monitoring of disease progres-
sion, provided that it is performed at regular intervals126(D).
The initial radiographic signs include increased amounts 
of soft tissues and juxta-articular osteopenia. More charac-
teristic signs of RA, such as reduced joint space and bone ero-
sion, appear later in the disease course. 
The presence of bone erosion during the early stages of 
RA represents a risk factor for the development of persistent 
arthritis127(B). This factor is associated with functional limita-
tion and thus with poorer prognosis128(B).
When erosions are identifi ed by radiography (15% preva-
lence), the diagnostic probability increases to 100%. However, 
as negative fi ndings do not reduce the probability (18%), they 
do not rule out a RA diagnosis129(B).
In patients with strong clinical suspicion of RA but nega-
tive RF serology and radiography, the presence of anti-CCP 
antibodies and erosions on MRI are highly specifi c for RA 
diagnosis130(B).
In RA patients, the sensitivity of MRI for the detection 
of erosions is greater than that of conventional radiogra-
phy. Conventional radiography detected 89% of erosions 
in the MCP joint bones and 15.8% in the wrist bones; these 
were lower than the MRI detection rates of 100% and 69%, 
respectively131(B).
The diagnostic accuracy of conventional radiography in 
the detection of wrist bone erosions in RA patients was 63%, 
whereas the accuracy of MRI was 77%132(B).
The diagnostic sensitivity of radiography for the detection 
of MCP joint bone erosions in RA patients was 14%, compared 
to 66% with MRI133(B).
In RA patients who were followed-up for two years, radi-
ography identifi ed damage progression in 40% of the cases 
(total Larsen score) and 15% of the MCP joint bones (Larsen 
score). The accuracy of plain radiography in the identifi cation 
of damage progression was similar to that of MRI134(B).
Detection of erosions by means of the E score in RA pa-
tients was lower on radiographic assessment (13.1 ± 8.3) than 
on MRI (28.8 ± 10.0)135(B).
In a population of RA patients with joint erosions (95% 
prevalence), radiography identifi ed 59% of the cases, com-
pared to 95% by MRI136(B).
Radiography of the hands of RA patients identifi ed 50% 
fewer erosions than MRI, although the identifi cation of radio-
logical progression was similar with both methods137(B).
In a population of RA patients with a 43% prevalence of 
erosions, radiography increased the diagnostic probability to 
80% for cases with positive fi ndings, and ruled out a diagnosis 
in 85% for those with negative fi ndings. After a 3-year follow-
up period, the identifi cation of erosions on radiography de-
creased to 81% and 60%, respectively138(B).
In a population of patients with arthritis, 36% of whom 
were diagnosed with RA, diagnostic radiography increased 
the probability of RA to 50%, but when the results were nega-
tive, the probability decreased to 33%139(B).
Radiographic assessment of RA patients only slightly in-
creased the probability of distinguishing between RF seropos-
itive and seronegative cases. In a population with a 59% prev-
alence of RF seropositive cases, positive radiographic fi ndings 
(destruction) increased the probability to 66%, and a lack of 
radiographic fi ndings decreased it to 47%140(B).
Recommendation
Conventional radiography must be used in diagnostic and 
prognostic assessments of RA. When needed and available, US 
and MRI should also be used. 
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9. Is ultrasound superior to conventional 
radiography in the diagnosis and establishment 
of prognosis of RA?
The sensitivity of musculoskeletal US and MRI for the detec-
tion of structural damage was superior to that of conven-
tional radiography141(D).
US is useful for early detection, as well as the monitor-
ing of infl ammatory activity and signs of joint destruction 
when performed by an operator with signifi cant experience 
in musculoskeletal diseases135(B).
Compared to MRI, the cost of US is lower, and it is not 
contraindicated for patients with metallic implants or claus-
trophobia. Additionally, US permits dynamic assessments of 
the joints and bilateral comparisons, as well as evaluations 
of other anatomical structures134(B)141,143(D).
The use of power and colour Doppler might provide com-
plementary information and thus contribute to characteri-
sations of infl ammatory activity144(D).
Positive and negative US fi ndings, when used to identify 
joint infl ammation in RA patients, permits defi nite diagno-
ses in 79% and 55% of the cases, respectively. These results 
are similar those of radiography (Sharp score) when it ex-
hibits positive fi ndings (74%), but superior when the radio-
graphic fi ndings are negative (38%)145(B).
Using MRI as the gold-standard (as in the present study), 
US was superior to radiography in the detection of bone ero-
sions in patients with recent RA, whereby the LR+ values 
were 31 and 20, respectively. Based on a lesion prevalence of 
50%, in cases with positive fi ndings, the diagnostic probabili-
ties of US and radiography increase to 99% and 97%, respec-
tively. Therefore, the utility of both methods is similar135(B).
Relative to the detection of erosions in RA patients, when 
US exhibits positive fi ndings, it achieves a diagnostic certain-
ty of 82% and for negative fi ndings, a certainty rate of 61%, 
compared to 95% and 55%, respectively, for radiography146(B).
The sensitivity and specifi city of US in the detection of 
infl ammatory signs and interphalangeal joint destruction 
in RA patients were 59% and 98%, respectively, compared 
to 42% and 99% for radiography, respectively. The diagnostic 
certainties relative to US and conventional radiography were 
97% and 98%, respectively, when those results were positive 
and 71% and 63%, respectively, when they were negative147(B).
The sensitivity and specifi city of US in the detection of 
MCP joint erosions in the of RA patients were 79% and 97%, 
respectively, compared to 32% and 98% for conventional ra-
diography, respectively. The diagnostic certainties relative to 
US and conventional radiography were 96% and 94%, respec-
tively, when those results were positive and 82% and 46%, 
respectively, when they were negative148(B).
The sensitivity and specifi city of US in the detection of 
glenohumeral joint erosions in RA patients were 74% and 
75%, respectively, compared to 67% and 100% for radiogra-
phy, respectively. The diagnostic certainties relative to US 
and conventional radiography were 75% and 100%, respec-
tively, when those results were positive and 74% and 75%, 
respectively, when they were negative149(B).
The diagnostic accuracy of US in the identifi cation of ero-
sions in RA patients was 84% and was thus superior to that 
of radiography (73%).  However, when only the tests with 
positive fi ndings were considered for analysis, the LR of 
US was lower (5 versus 13), which indicates less diagnostic 
certainty150(B).
In patients with early RA, US found erosions that were 
not identifi ed by radiography in 19.3% of the cases, but 
failed to diagnose 8.8% of the cases that were identifi ed 
by radiography. The combination of both methods permit-
ted the diagnosis of 45.6% of the lesions in that patient 
population151(B).
In patients with early RA, US correlated with disease ac-
tivity (DAS28) and functional capacity (HAQ) scores at 12 
months of follow-up152(B).
In patients with early RA, US increased the detection of 
erosions in 42.0% of the cases at the time of diagnosis and 
after 9 months of follow-up, compared to radiography153(B).
The detection of joint lesions in RA patients was greater 
with US versus radiography; specifi cally, US detection was 
5% greater at the time of diagnosis, and 23% greater after 
seven years of follow-up154(B). However, in another study, 
radiography identifi ed a larger number of erosions in RA 
patients, compared to US (37% and 30%, respectively). After 
six months, the rates were 48% and 41%, respectively155(B).
After accounting for the number of humeral erosions 
(greater tuberosity, anteromedial, and posterolateral) in RA 
patients, the diagnostic certainties of US and radiography 
were 90% and 40%, respectively, when the fi ndings were 
positive and 96% and 39%, respectively, when the fi ndings 
were negative152(B).
Recommendation
US might contribute to the diagnosis of joint erosions in RA 
patients, as well to the monitoring of disease progression. 
10. Is magnetic resonance superior to 
conventional radiography and ultrasound for the 
diagnosis and establishment of prognosis of RA?
MRI is the most sensitive method with which to detect the 
changes associated with the early stages of RA. It permits 
the assessment of structural alterations of the soft tissues, 
bone, and cartilage, in addition to erosions at an earlier 
stage than conventional radiography138(B).
In addition to the features identifi ed by conventional 
radiography, MRI is further able to detect bone swelling, 
which was shown to be a predictor of bone erosion135(B).
In Brazil, factors such as the high cost and lack of stan-
dardisation limit the use of MRI in clinical practice.
The results of MRI relative to RA diagnosis vary widely 
as a function of the applied criteria and the investigated 
population. Thus, the sensitivity varies from 20% to 100%, 
and the specifi city from 0% to 100%136,156-158(B). Additionally, 
the results of MRI relative to RA progression vary widely, 
with a sensitivity range from 18% to 100% and a specifi c-
ity range from 6% to 97%156,159-161(B). Furthermore, the use 
of MRI in the management of patients with recent RA does 
not seem to be cost-effective when compared to standard 
diagnostic and prognostic assessments162(B).
R E V  B R A S  R E U M A T O L .  2 0 1 3 ; 5 3 ( 2 ) : 1 4 1 – 1 5 7150
In RA patients, MRI (Outcome Measures in Rheumatology 
– OMERACT - defi nition) permits the diagnosis of erosions 
(hands or wrists) with 35%–90% sensitivity and 35%–90% 
specifi city, bone swelling (hands, wrists, or MCP joints) with 
32.5%–65% sensitivity and 82.5%–100% specifi city, and synovi-
tis (hands or wrists) with 40-80% sensitivity and 57.7%–92.5% 
specifi city163(B).
Compared to MRI, when the fi ndings were positive, con-
ventional radiography could diagnose MCP and PIP joint ero-
sions with certainty in 98%–100% of the cases, and US in 86%–
7% of the cases. When the fi ndings were negative, the rates 
were 84% and 93%, respectively 135,155(B).
The diagnostic accuracy of Doppler US for the identifi ca-
tion of joint infl ammation in RA patients was 75%, compared 
to MRI164(B).
Using computed tomography (CT) as the gold-standard for 
the diagnosis of erosions in the wrists of RA patients, when 
the fi ndings were positive, MRI accurately diagnosed 90% of 
the cases, compared to conventional radiography138,154(B).
Using high-fi eld MRI as the gold-standard for the diagnosis 
of erosions in the wrists and MCP joints of RA patients, when 
the fi ndings were positive, limb MRI accurately diagnosed 88% 
to 93% of the cases, compared to conventional radiography 
(94%–98%) and US (82%)165,166(B).
A combination of MRI synovitis, swelling, and erosion 
scores permitted the identifi cation of RA patient responses to 
TNF-α inhibitor treatment at a 12-month follow-up167(B).
As a method for long-term functional assessments in RA 
patients, MRI identifi ed improvements only in 29% of the 
cases, compared to the functional status (assessed by doctors 
and patients)168(B).
MRI (bone swelling) and US (infl ammation) exhibited simi-
lar abilities to identify the progression of erosion in RA pa-
tients (using the Rheumatoid Arthritis MRI Scoring System 
– RAMRIS – as the gold standard) over a 12-month follow-up 
period152(B).
The progression of erosion was identifi ed by MRI (OMER-
ACT) in 23% of patients with RA over a 5-year period, compared 
with 40% by conventional radiography (Larsen score)140(B).
Recommendation
MRI is the most sensitive method with which to detect the 
changes associated with the early stages of RA. It permits the 
assessment of structural alterations of the soft tissues, bone, 
and cartilage, in addition to erosions at an earlier stage than 
conventional radiography. In Brazil, factors such as the high 
cost and lack of standardisation have limited the use of MRI 
in clinical practice.
Table 5 summarises the advantages and disadvantages of 
the imaging methods used to assess RA patients.
Conclusion
The present guidelines were elaborated by the Commission 
of Rheumatoid Arthritis of the Brazilian Society of Rheuma-
tology to formulate recommendations for the diagnosis and 
initial assessment of RA in Brazil. Due to the country’s territo-
rial extension and the diversity of its macro-regions, local dif-
ferences relative to differential diagnoses and access to some 
(laboratory or imaging) technologies might occur.
RA diagnosis is of paramount importance, especially in the 
earliest stages.
Lack of diagnosis means a lack of appropriate treatment 
and, consequently, an increased risk of the development of 
persistent infl ammation and progressive joint damage. Rheu-
matologists must be included as early as possible in assess-
ments of patients with arthritis due to their wider experience 
and familiarity with the possible differential diagnoses and 
investigational approaches. 
Despite the recent publication of guidelines for the diagno-
sis of RA, a revision of this subject that accounts for particular 
Brazilian features is relevant.
Therefore, the establishment of recommendations for RA 
ultimately seeks to defi ne and provide a solid basis for Brazil-
ian rheumatologists with data from controlled trials to pro-
mote a homogeneous approach to diagnosis within the Bra-
zilian socioeconomic context. 
Table 5 – Advantages and disadvantages of the imaging methods used to assess patients with rheumatoid arthritis.
Methods Advantages Disadvantages 
Conventional radiography - Low cost
- Easy access
- Two-dimensional representation of 3-D lesions
- Exposure to ionising radiation
- Low sensitivity for early bone damage
Ultrasound - Intermediate cost
- No ionising radiation
- Allows assessing several joints
- Guides diagnostic and therapeutic 
interventions
- Early detection of cartilage and bone structural 
damage
- Detection of infl ammatory activity by means 
of power Doppler
- Operator-dependent test
- Poor sensitivity to detect changes in deep joints (hips)
Magnetic resonance -  High sensitivity
- No ionising radiation
- Complementation using contrast agents
- Early detection of bone swelling, cartilage and 
bone structural damage
- High cost
- Limited equipment availability
- Long testing time
- Limited to one joint per exam (e.g., knee, hand)
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Because the knowledge relative to RA increases rapidly, 
the corresponding recommendations should be updated on a 
periodic and regular basis. 
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